Pre-made Opicinumab benchmark antibody ( Whole mAb, anti-LINGO1 therapeutic antibody, Anti-LERN1/LRRN6A/MRT64/UNQ201 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Opicinumab biosimilar, Whole mAb, Anti-LINGO1 Antibody: Anti-LERN1/LRRN6A/MRT64/UNQ201 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Opicinumab (BIIB033) is a fully human monoclonal antibody designed for the treatment of multiple sclerosis, acute optic neuritis (AON), and other associated demyelinating diseases. A biologic drug, it is designed to function as a LINGO-1 protein antagonist, known as “Anti-Lingo-1”.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	List Price(In USD)	Discount off	Discount Price
GMP-Bios-ab-407-1mg	1mg	3090	Inquiry	Inquiry

Size： 1mg | 10mg | 100mg

Description

Products Name (INN Index)	Pre-Made Opicinumab biosimilar, Whole mAb, Anti-LINGO1 Antibody: Anti-LERN1/LRRN6A/MRT64/UNQ201 therapeutic antibody
INN Name	Opicinumab
Target	LINGO1
Format	Whole mAb
Derivation	Human
Species Reactivity	Human
CH1 Isotype	IgG1
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Discontinued
100% SI Structure	4oqt:HL
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2015
Year Recommended	2016
Companies	Biogen Idec;Dyax;Biogen
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Multiple sclerosis;Optic neuritis
Development Tech	Dyax Human Phage Display